False Advertising

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

Lilly’s stronger-than-expected Q2 with raised guidance highlights widening commercial momentum while Novo struggles to reassure investors as pipeline setbacks and guidance cool market confidence.